Full Breakdown
FDA Approves Denali Therapeutics' Avlayah for Hunter Syndrome Treatment
3/26/2026, 1:18:39 PM
Overview of the Approval
On March 25, 2026, the U.S. Food and Drug Administration (FDA) granted approval to Denali Therapeutics for its enzyme replacement therapy, Avlayah, aimed at treating Hunter syndrome in children. This marks Denali's first regulatory approval in the United States. Hunter syndrome is a rare genetic disorder that predominantly affects males and is characterized by the accumulation of sugar molecules in the brain and body, leading to developmental delays, cognitive decline, and behavioral abnormalities. Approximately 500 individuals in the U.S. are diagnosed with this condition.
Treatment Details
Avlayah is administered as a once-weekly infusion and has been approved for both presymptomatic and symptomatic pediatric patients. The therapy's list price is set at $5,200 per 150 milligrams per single-use vial. The FDA's accelerated approval was based on a surrogate endpoint that measured the reduction of heparan sulfate, a sugar molecule that accumulates due to Hunter syndrome and is associated with organ damage. The FDA indicated that this endpoint is reasonably likely to predict the clinical benefit of Avlayah, although Denali is conducting further trials to confirm these findings.
Market Implications
Following the announcement, Denali's shares rose by 8.4%, reaching $22.74. Analysts, including Wedbush's Laura Chico, view the approval as a positive sign for other therapies utilizing surrogate endpoints, especially in light of the FDA's historically cautious approach under the leadership of Vinay Prasad, who has expressed skepticism towards such measures. Notably, Prasad is set to leave the agency at the end of April.
Safety Considerations
Avlayah's approval includes a boxed warning for severe allergic reactions, the most serious type of warning issued by the FDA. Prior to Avlayah's approval, the only FDA-approved enzyme replacement therapy for Hunter syndrome in the U.S. was Takeda Pharmaceuticals' Elaprase, which has been available since 2006 but only addresses the physical symptoms of the disorder.
Criticism & Opposition
Despite the approval, there are concerns regarding the reliance on surrogate endpoints for regulatory decisions. Critics argue that while these measures can expedite access to treatments, they may not always accurately reflect clinical benefits, potentially putting patients at risk. The ongoing confirmatory trial for Avlayah will be crucial in addressing these concerns and ensuring the therapy's efficacy.
What's Next
Denali Therapeutics is expected to continue its clinical trials to verify the clinical benefits of Avlayah. The outcomes of these studies will be essential for the therapy's long-term approval and acceptance in the medical community.
